BACKGROUND O
: O
Calcitriol O
therapy O
suppresses O
serum O
levels O
of O
parathyroid O
hormone O
( O
PTH O
) O
in O
patients O
with O
renal B
failure I
but O
has O
several O
drawbacks O
, O
including O
hypercalcemia B
and O
/ O
or O
marked O
suppression B
of I
bone I
turnover I
, O
which O
may O
lead O
to O
adynamic B
bone I
disease I
. O

The O
patient O
was O
admitted O
with O
a O
pulmonary B
- I
renal I
syndrome I
with O
hemoptysis B
, O
rapidly O
progressive O
renal B
failure I
, O
and O
hypoxemia B
that O
required O
mechanical O
ventilation O
in O
the O
intensive O
care O
unit O
. O

Ten O
patients O
who O
had O
Parkinson B
' I
s I
disease I
with O
disabling O
dyskinesia B
were O
included O
in O
this O
study O
to O
evaluate O
the O
role O
of O
mental O
( O
mental O
calculation O
) O
and O
motor O
( O
flexion O
/ O
extension O
of O
right O
fingers O
, O
flexion O
/ O
extension O
of O
left O
fingers O
, O
flexion O
/ O
extension O
of O
the O
neck O
, O
speaking O
aloud O
) O
tasks O
on O
the O
worsening O
of O
peak O
- O
dose O
dyskinesia B
following O
administration O
of O
an O
effective O
single O
dose O
of O
apomorphine O
. O

OBJECTIVE O
: O
To O
quantify O
specific O
clinical O
predictors O
of O
reduction B
in I
renal I
function I
in O
patients O
with O
CHF B
who O
are O
prescribed O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
. O

Apomorphine O
: O
an O
underutilized O
therapy O
for O
Parkinson B
' I
s I
disease I
. O

Apomorphine O
was O
the O
first O
dopaminergic O
drug O
ever O
used O
to O
treat O
symptoms O
of O
Parkinson B
' I
s I
disease I
. O

While O
powerful O
antiparkinsonian O
effects O
had O
been O
observed O
as O
early O
as O
1951 O
, O
the O
potential O
of O
treating O
fluctuating O
Parkinson B
' I
s I
disease I
by O
subcutaneous O
administration O
of O
apomorphine O
has O
only O
recently O
become O
the O
subject O
of O
systematic O
study O
. O

Given O
the O
marked O
degree O
of O
efficacy O
of O
subcutaneous O
apomorphine O
treatment O
in O
fluctuating O
Parkinson B
' I
s I
disease I
, O
this O
approach O
seems O
to O
deserve O
more O
widespread O
clinical O
use O
. O

OBJECTIVE O
: O
The O
pharmacological O
response O
to O
drugs O
that O
act O
on O
the O
cholinergic O
system O
of O
the O
iris O
has O
been O
used O
to O
predict O
deficits O
in O
central O
cholinergic O
functioning O
due O
to O
diseases O
such O
as O
Alzheimer B
' I
s I
disease I
, O
yet O
correlations O
between O
central O
and O
peripheral O
responses O
have O
not O
been O
properly O
studied O
. O

OUTCOME O
MEASURES O
: O
Pupil O
size O
at O
time O
points O
after O
administration O
of O
tropicamide O
and O
pilocarpine O
; O
scopolamine O
- O
induced O
impairment B
in I
word I
recall I
. O

Compared O
with O
the O
young O
group O
, O
the O
elderly O
group O
had O
greater O
scopolamine O
- O
induced O
impairment B
in I
word I
recall I
60 O
, O
90 O
and O
120 O
minutes O
after O
administration O
( O
p O
< O
0 O
. O
05 O
) O
. O

We O
hypothesize O
that O
it O
may O
cause O
some O
damage B
to I
the I
muscle I
of O
spinal B
cord I
injury I
patients O
. O

Patient O
demographics O
, O
history O
of O
underlying O
drug O
or O
alcohol O
- O
related O
seizure B
disorder O
, O
estimated O
time O
from O
seizure B
to O
sample O
collection O
, O
history O
or O
suspicion O
of O
cocaine B
or I
amphetamine I
abuse I
, O
results O
of O
clinical O
urine O
testing O
for O
drugs O
of O
abuse O
, O
and O
assay O
results O
were O
recorded O
without O
patient O
identifiers O
. O

Positive O
test O
results O
were O
more O
common O
in O
patient O
visits O
where O
there O
was O
a O
history O
or O
suspicion O
of O
cocaine B
or I
amphetamine I
abuse I
( O
p O
< O
0 O
. O
0005 O
) O
. O

He O
had O
been O
taking O
VPA O
for O
treatment O
of O
idiopathic O
generalized O
tonic B
- I
clonic I
convulsions I
since O
he O
was O
56 O
years O
old O
. O

Calcitonin O
gene O
- O
related O
peptide O
levels O
during O
nitric O
oxide O
- O
induced O
headache B
in O
patients O
with O
chronic O
tension B
- I
type I
headache I
. O

In O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
CGRP O
during O
headache B
induced O
by O
the O
NO O
donor O
glyceryl O
trinitrate O
( O
GTN O
) O
in O
16 O
patients O
with O
chronic O
tension B
- I
type I
headache I
and O
16 O
healthy O
controls O
. O

METHODS O
: O
Forty O
- O
three O
Caucasian O
patients O
with O
primary O
open B
- I
angle I
glaucoma I
or O
ocular B
hypertension I
with O
a O
mean O
( O
+ O
/ O
- O
SD O
) O
age O
of O
63 O
( O
+ O
/ O
- O
8 O
) O
years O
were O
randomized O
and O
crossed O
over O
in O
a O
double O
- O
masked O
manner O
to O
14 O
days O
of O
treatment O
with O
placebo O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
timolol O
solution O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
or O
timolol O
gellan O
( O
morning O
in O
both O
eyes O
with O
placebo O
in O
the O
evening O
) O
. O

BACKGROUND O
: O
Preclinical O
studies O
of O
intrathecal O
adenosine O
suggest O
it O
may O
be O
effective O
in O
the O
treatment O
of O
acute B
and I
chronic I
pain I
in O
humans O
, O
and O
preliminary O
studies O
in O
volunteers O
and O
patients O
with O
a O
Swedish O
formulation O
of O
adenosine O
suggests O
it O
may O
be O
effective O
in O
hypersensitivity B
states O
but O
not O
with O
acute O
noxious O
stimulation O
. O

BACKGROUND O
: O
Heparin O
- O
induced O
thrombocytopenia B
presents O
5 O
to O
12 O
days O
after O
heparin O
exposure O
, O
with O
or O
without O
arterial B
or I
venous I
thromboemboli I
. O

Torsade B
de I
pointes I
induced O
by O
metoclopramide O
in O
an O
elderly O
woman O
with O
preexisting O
complete O
left B
bundle I
branch I
block I
. O

We O
report O
on O
a O
92 O
- O
year O
- O
old O
woman O
with O
preexisting O
complete O
left B
bundle I
branch I
block I
who O
developed O
torsade B
de I
pointes I
after O
intravenous O
and O
oral O
administration O
of O
metoclopramide O
. O

Lesions O
of O
the O
substantia O
nigra O
are O
therefore O
associated O
with O
erectile B
dysfunction I
in O
rats O
and O
may O
serve O
as O
a O
model O
to O
study O
erectile B
dysfunction I
in O
Parkinson B
' I
s I
disease I
. O

Force O
overflow O
and O
levodopa O
- O
induced O
dyskinesias B
in O
Parkinson B
' I
s I
disease I
. O

We O
assessed O
force O
coordination O
of O
the O
hand O
in O
Parkinson B
' I
s I
disease I
and O
its O
relationship O
to O
motor O
complications O
of O
levodopa O
therapy O
, O
particularly O
to O
levodopa O
- O
induced O
dyskinesias B
( O
LID B
) O
. O

We O
studied O
two O
groups O
of O
Parkinson B
' I
s I
disease I
patients O
with O
( O
Parkinson B
' I
s I
disease I
+ O
LID B
, O
n O
= O
23 O
) O
and O
without O
levodopa O
- O
induced O
dyskinesias B
( O
Parkinson B
' I
s I
disease I
- O
LID B
, O
n O
= O
10 O
) O
, O
and O
age O
- O
matched O
healthy O
controls O
. O

We O
studied O
two O
groups O
of O
Parkinson B
' I
s I
disease I
patients O
with O
( O
Parkinson B
' I
s I
disease I
+ O
LID B
, O
n O
= O
23 O
) O
and O
without O
levodopa O
- O
induced O
dyskinesias B
( O
Parkinson B
' I
s I
disease I
- O
LID B
, O
n O
= O
10 O
) O
, O
and O
age O
- O
matched O
healthy O
controls O
. O

We O
studied O
two O
groups O
of O
Parkinson B
' I
s I
disease I
patients O
with O
( O
Parkinson B
' I
s I
disease I
+ O
LID B
, O
n O
= O
23 O
) O
and O
without O
levodopa O
- O
induced O
dyskinesias B
( O
Parkinson B
' I
s I
disease I
- O
LID B
, O
n O
= O
10 O
) O
, O
and O
age O
- O
matched O
healthy O
controls O
. O

The O
motor O
score O
of O
the O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
, O
a O
dyskinesia B
score O
and O
force O
in O
a O
grip O
- O
lift O
paradigm O
were O
assessed O
ON O
and O
OFF O
levodopa O
. O

A O
pathological O
increase O
of O
forces O
was O
seen O
in O
ON O
- O
state O
in O
Parkinson B
' I
s I
disease I
+ O
LID B
only O
. O

In O
Parkinson B
' I
s I
disease I
+ O
LID B
, O
the O
force O
involved O
in O
pressing O
down O
the O
object O
before O
lifting O
was O
significantly O
increased O
by O
levodopa O
( O
by O
61 O
% O
, O
P O
< O
0 O
. O
05 O
) O
. O

In O
contrast O
, O
no O
excessive O
force O
was O
found O
in O
Parkinson B
' I
s I
disease I
- O
LID B
. O

Peak O
grip O
force O
in O
ON O
- O
state O
was O
140 O
% O
( O
P O
< O
0 O
. O
05 O
) O
higher O
in O
Parkinson B
' I
s I
disease I
+ O
LID B
than O
in O
Parkinson B
' I
s I
disease I
- O
LID B
, O
while O
static O
grip O
force O
was O
increased O
by O
138 O
% O
( O
P O
< O
0 O
. O
01 O
) O
between O
groups O
. O

Peak O
grip O
force O
in O
ON O
- O
state O
was O
140 O
% O
( O
P O
< O
0 O
. O
05 O
) O
higher O
in O
Parkinson B
' I
s I
disease I
+ O
LID B
than O
in O
Parkinson B
' I
s I
disease I
- O
LID B
, O
while O
static O
grip O
force O
was O
increased O
by O
138 O
% O
( O
P O
< O
0 O
. O
01 O
) O
between O
groups O
. O

This O
study O
focuses O
on O
behavioral O
syndromes O
that O
may O
used O
as O
models O
for O
Parkinson B
' I
s I
disease I
, O
or O
tardive B
dyskinesia I
, O
and O
its O
response O
after O
glutamatergic O
blockage O
. O

Reserpine O
also O
produced O
tremor B
and O
catalepsy B
, O
which O
are O
signs O
suggestive O
of O
Parkinson B
' I
s I
disease I
. O

Ribavirin O
is O
licensed O
in O
aerosol O
form O
for O
the O
treatment O
of O
respiratory B
syncytial I
virus I
infection I
, O
and O
orally O
in O
combination O
with O
interferon O
to O
treat O
hepatitis B
C I
. O

Eighteen O
hours O
after O
the O
overdose B
he O
had O
two O
generalised O
tonic B
- I
clonic I
seizures I
. O

Levodopa O
- O
induced O
dyskinesias B
have O
been O
reported O
in O
Parkinson B
' I
s I
disease I
and O
multiple B
system I
atrophy I
. O

Methylphenidate O
- O
induced O
obsessive B
- I
compulsive I
symptoms I
in O
an O
elderly O
man O
. O

An O
82 O
- O
year O
- O
old O
man O
with O
treatment B
- I
resistant I
depression I
and O
early O
Alzheimer B
' I
s I
disease I
was O
started O
on O
methylphenidate O
. O

An O
82 O
- O
year O
- O
old O
man O
with O
treatment B
- I
resistant I
depression I
and O
early O
Alzheimer B
' I
s I
disease I
was O
started O
on O
methylphenidate O
. O

Significant O
obsessive B
- I
compulsive I
behavior I
ensued O
but O
diminished O
over O
several O
weeks O
when O
methylphenidate O
was O
replaced O
by O
fluvoxamine O
. O

The O
patient O
had O
no O
prior O
psychiatric B
history O
, O
but O
he O
had O
a O
sister O
with O
obsessive B
- I
compulsive I
disorder I
. O

Renal B
function I
significantly I
deteriorated I
in O
the O
group O
pretreated O
with O
furosemide O
( O
p O
< O
0 O
. O
005 O
by O
ANOVA O
) O
, O
with O
a O
rise O
in O
serum O
creatinine O
from O
145 O
+ O
/ O
- O
13 O
to O
182 O
+ O
/ O
- O
16 O
mumol O
/ O
l O
at O
24 O
h O
, O
while O
no O
change O
occurred O
in O
the O
control O
group O
( O
from O
141 O
+ O
/ O
- O
6 O
to O
142 O
+ O
/ O
- O
7 O
mumol O
/ O
l O
) O
. O

Hemolytic B
- I
uremic I
syndrome I
associated O
with O
ingestion O
of O
quinine O
. O

Hemolytic B
- I
uremic I
syndrome I
following O
quinine O
ingestion O
is O
a O
newly O
described O
phenomenon O
, O
with O
just O
two O
previous O
descriptions O
of O
4 O
cases O
in O
the O
literature O
. O

Quinine O
- O
associated O
hemolytic B
- I
uremic I
syndrome I
probably O
occurs O
more O
often O
than O
is O
recognized O
. O

Glomerular B
and I
tubular I
injury I
was O
monitored O
and O
correlated O
to O
the O
activity O
or O
expression O
of O
respiratory O
chain O
components O
. O

RESULTS O
: O
The O
' O
long O
- O
term O
' O
group O
had O
significant O
glomerular B
and I
tubular I
lesions I
, O
depressed O
activities O
of O
mtDNA O
- O
encoded O
NADH O
dehydrogenase O
and O
cytochrome O
- O
c O
oxidase O
( O
COX O
) O
and O
increased O
citrate O
synthase O
activity O
. O

Among O
all O
animals O
, O
glomerular B
and I
tubular I
injury I
were O
inversely O
correlated O
with O
mtDNA O
levels O
, O
mtDNA O
- O
encoded O
respiratory O
chain O
activities O
and O
with O
the O
expression O
of O
the O
mtDNA O
- O
encoded O
respiratory O
chain O
subunit O
COX O
- O
I O
. O

Atrial B
fibrillation I
following O
chemotherapy O
for O
stage O
IIIE O
diffuse O
large O
B O
- O
cell O
gastric B
lymphoma I
in O
a O
patient O
with O
myotonic B
dystrophy I
( O
Steinert B
' I
s I
disease I
) O
. O

A O
resurgence O
of O
interest O
in O
the O
surgical O
treatment O
of O
Parkinson B
' I
s I
disease I
( O
PD B
) O
came O
with O
the O
rediscovery O
of O
posteroventral O
pallidotomy O
by O
Laitinen O
in O
1985 O
. O

Stimulation O
often O
produces O
an O
improvement O
in O
the O
hyper B
- I
or I
dyskinetic I
upper O
limbs O
, O
but O
increases O
the O
" O
freezing O
" O
phenomenon O
in O
the O
lower O
limbs O
at O
the O
same O
time O
. O

The O
mean O
highest O
BIS O
score O
corresponding O
to O
the O
inability B
to I
repeat I
words I
was O
81 O
. O
5 O
( O
95 O
% O
CI O
= O
78 O
. O
1 O
to O
84 O
. O
8 O
) O
. O

Calcium O
carbonate O
toxicity B
: O
the O
updated O
milk B
- I
alkali I
syndrome I
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

OBJECTIVE O
: O
To O
describe O
3 O
patients O
with O
calcium O
carbonate O
- O
induced O
hypercalcemia B
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk B
- I
alkali I
syndrome I
. O

METHODS O
: O
We O
report O
the O
clinical O
and O
laboratory O
data O
in O
3 O
patients O
who O
presented O
with O
severe O
hypercalcemia B
( O
corrected O
serum O
calcium O
> O
or O
= O
14 O
mg O
/ O
dL O
) O
and O
review O
the O
pertinent O
literature O
on O
milk B
- I
alkali I
syndrome I
. O

In O
addition O
to O
our O
highlighted O
cases O
, O
we O
review O
the O
history O
, O
classification O
, O
pathophysiologic O
features O
, O
and O
treatment O
of O
milk B
- I
alkali I
syndrome I
and O
summarize O
the O
cases O
reported O
from O
early O
1995 O
to O
November O
2003 O
. O

CONCLUSION O
: O
Milk B
- I
alkali I
syndrome I
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia B
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium O
carbonate O
in O
susceptible O
persons O
. O

Leukocytoclastic B
vasculitis I
( O
LV B
) O
is O
primarily O
a O
cutaneous B
small I
vessel I
vasculitis I
, O
though O
systemic O
involvement O
may O
be O
encountered O
. O

rTMS O
at O
1 O
Hz O
was O
observed O
to O
markedly O
reduce O
drug B
- I
induced I
dyskinesias I
, O
whereas O
5 O
- O
Hz O
rTMS O
induced O
a O
slight O
but O
not O
significant O
increase O
. O

Amisulpride O
related O
tic B
- I
like I
symptoms I
in O
an O
adolescent O
schizophrenic B
. O

However O
, O
there O
are O
two O
case O
reports O
that O
show O
tic B
- I
like I
symptoms I
, O
including O
motor O
and O
phonic O
variants O
, O
occurring O
during O
treatment O
with O
quetiapine O
or O
clozapine O
. O

The O
tic B
- I
like I
symptoms I
resolved O
completely O
after O
we O
reduced O
the O
dose O
of O
amisulpride O
down O
to O
800 O
mg O
per O
day O
. O

No O
more O
tic B
- I
like I
symptoms I
or O
other O
side O
effects O
have O
been O
reported O
. O

Together O
with O
previously O
reported O
cases O
, O
our O
patient O
suggests O
that O
tic B
- I
like I
symptoms I
might O
occur O
in O
certain O
vulnerable O
individuals O
during O
treatment O
with O
atypical O
antipsychotics O
such O
as O
quetiapine O
, O
clozapine O
, O
or O
amisulpride O
. O

Ophthalmological O
assessment O
revealed O
features O
of O
chloroquine O
retinopathy B
, O
cardiac O
assessment O
revealed O
features O
of O
heart B
failure I
and O
a O
complete O
heart B
block I
with O
right B
bundle I
branch I
block I
pattern O
. O

The O
choline O
acetyltransferase O
( O
ChAT O
) O
activator O
, O
which O
enhances O
cholinergic O
transmission O
via O
an O
augmentation O
of O
the O
enzymatic O
production O
of O
acetylcholine O
( O
ACh O
) O
, O
is O
an O
important O
factor O
in O
the O
treatment O
of O
Alzheimer B
' I
s I
disease I
( O
AD B
) O
. O

The O
extent O
to O
which O
status B
epilepticus I
causes O
deficits B
in I
auditory I
discrimination I
is O
unknown O
. O

Status B
epilepticus I
in O
rat O
causes O
an O
age O
- O
dependent O
, O
long O
- O
term O
impairment B
in I
auditory I
discrimination I
. O

This O
impairment O
may O
explain O
one O
cause O
of O
impaired B
auditory I
location I
discrimination I
in O
humans O
. O

Hemoglobin O
concentrations O
decrease O
mainly O
as O
a O
result O
of O
ribavirin O
- O
induced O
hemolysis B
, O
and O
this O
anemia B
can O
be O
problematic O
in O
patients O
with O
HCV B
infection I
, O
especially O
those O
who O
have O
comorbid O
renal B
or I
cardiovascular I
disorders I
. O

OUTCOME O
: O
All O
3 O
patients O
had O
some O
permanent O
loss B
of I
visual I
function I
. O

The O
effect O
of O
induced O
hypertension B
instituted O
after O
a O
2 O
- O
h O
delay O
following O
middle B
cerebral I
artery I
occlusion I
( O
MCAO B
) O
on O
brain B
edema I
formation O
and O
histochemical O
injury O
was O
studied O
. O

Peripheral O
iron O
dextran O
induced O
degeneration B
of I
dopaminergic I
neurons I
in O
rat O
substantia O
nigra O
. O

Iron O
accumulation O
is O
considered O
to O
be O
involved O
in O
the O
pathogenesis O
of O
Parkinson B
' I
s I
disease I
. O

To O
demonstrate O
the O
relationship O
between O
peripheral O
iron O
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
( O
SN O
) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine O
hydroxylase O
( O
TH O
) O
immunohistochemistry O
, O
Perls O
' O
iron O
staining O
, O
and O
high O
performance O
liquid O
chromatography O
- O
electrochemical O
detection O
to O
study O
the O
degeneration B
of I
dopaminergic I
neurons I
and O
increased O
iron O
content O
in O
the O
SN O
of O
iron O
dextran O
overloaded O
animals O
. O

These O
results O
suggest O
that O
peripheral O
iron O
dextran O
can O
increase O
the O
iron O
level O
in O
the O
SN O
, O
where O
excessive O
iron O
causes O
the O
degeneration B
of I
dopaminergic I
neurons I
. O

For O
this O
reason O
, O
each O
clinician O
should O
recognize O
this O
entity O
in O
the O
differential O
diagnosis O
of O
PB O
- O
related O
asymptomatic O
chronic B
hepatic I
enzyme I
dysfunction I
. O

Disulfiram O
- O
induced O
transient O
optic B
and I
peripheral I
neuropathy I
: O
a O
case O
report O
. O

AIM O
: O
To O
report O
a O
case O
of O
optic B
and I
peripheral I
neuropathy I
after O
chronic O
use O
of O
disulfiram O
for O
alcohol B
dependence I
management O
. O

Highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
has O
significantly O
reduced O
morbidity O
and O
mortality O
of O
acquired B
immunodeficiency I
syndrome I
( O
AIDS B
) O
, O
but O
has O
resulted O
in O
an O
increase O
in O
cardiac B
and I
skeletal I
myopathies I
. O

CONCLUSIONS O
: O
The O
expression O
of O
Fas O
ligand O
in O
the O
myocardium O
, O
as O
identified O
in O
HIV O
- O
positive O
patients O
, O
might O
increase O
the O
susceptibility O
to O
HAART O
- O
induced O
cardiomyopathy B
due O
to O
activation O
of O
apoptotic O
pathways O
, O
resulting O
in O
cardiac B
dilation I
and I
dysfunction I
. O

Forty O
patients O
with O
a O
diagnosis O
consistent O
with O
a O
hematologic B
/ I
oncologic I
disorder I
that O
required O
treatment O
with O
an O
aminoglycoside O
were O
randomized O
to O
either O
conventional O
or O
extended O
- O
interval O
amikacin O
. O

A O
LD O
( O
10 O
) O
dose O
( O
8 O
mg O
doxorubicin O
/ O
kg O
, O
ip O
) O
administered O
on O
day O
43 O
of O
the O
HFD O
feeding O
regimen O
led O
to O
higher O
cardiotoxicity B
, O
cardiac B
dysfunction I
, O
lipid O
peroxidation O
, O
and O
80 O
% O
mortality O
in O
the O
obese B
( O
OB B
) O
rats O
in O
the O
absence O
of O
any O
significant O
renal B
or I
hepatic I
toxicity I
. O

Transplantation B
- I
associated I
microangiopathy I
( O
TMA B
) O
occurred O
in O
7 O
patients O
( O
29 O
% O
) O
, O
with O
2 O
cases O
of O
acute B
renal I
failure I
. O

Clinical O
evaluation O
included O
the O
use O
of O
the O
Unified O
Parkinson B
' I
s I
Disease I
Rating O
Scale O
( O
UPDRS O
) O
, O
Hoehn O
_ O
Yahr O
score O
and O
Schwab O
England O
activities O
of O
daily O
living O
( O
ADL O
) O
score O
in O
' O
on O
' O
- O
and O
' O
off O
' O
- O
drug O
conditions O
before O
surgery O
and O
6 O
months O
after O
surgery O
. O

The O
most O
frequent O
adverse O
events O
were O
hematological B
and I
gastrointestinal I
toxicities I
as O
well O
as O
neuropathy B
. O

In O
relatively O
healthy O
women O
, O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B
thrombo I
- I
embolism I
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B
( O
after O
three O
years O
) O
, O
breast B
cancer I
and O
gallbladder B
disease I
. O

Long O
- O
term O
oestrogen O
- O
only O
HT O
significantly O
increased O
the O
risk O
of O
venous B
thrombo I
- I
embolism I
, O
stroke B
and O
gallbladder B
disease I
( O
after O
one O
to O
two O
years O
, O
three O
years O
and O
seven O
years O
' O
use O
respectively O
) O
, O
but O
did O
not O
significantly O
increase O
the O
risk O
of O
breast B
cancer I
. O

Among O
women O
with O
cardiovascular B
disease I
, O
long O
- O
term O
use O
of O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B
thrombo I
- I
embolism I
. O
One O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
old O
women O
taking O
combined O
continuous O
HT O
and O
1637 O
taking O
oestrogen O
- O
only O
HT O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

The O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B
thrombo I
- I
embolism I
in O
women O
taking O
combined O
continuous O
HT O
: O
their O
absolute O
risk O
remained O
low O
, O
at O
less O
than O
1 O
/ O
500 O
. O

The O
current O
data O
showed O
that O
pilocarpine O
significantly O
delayed O
onset O
of O
arrhythmias B
, O
decreased O
the O
time O
course O
of O
ventricular B
tachycardia I
and I
fibrillation I
, O
reduced O
arrhythmia B
score O
, O
and O
increased O
the O
survival O
time O
of O
arrhythmic B
rats O
and O
guinea O
pigs O
. O

Metabotropic O
glutamate O
7 O
receptor O
subtype O
modulates O
motor O
symptoms O
in O
rodent O
models O
of O
Parkinson B
' I
s I
disease I
. O

Metabotropic O
glutamate O
( O
mGlu O
) O
receptors O
modulate O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
and O
represent O
promising O
therapeutic O
targets O
for O
symptomatic O
treatment O
of O
Parkinson B
' I
s I
disease I
( O
PD B
) O
. O

In O
addition O
, O
tacrine O
- O
loaded O
nanoparticles O
administration O
induced O
damage B
of I
neuronal I
cells I
in O
CA1 O
field O
of O
the O
hippocampus O
in O
all O
treated O
animals O
, O
while O
the O
saline O
solution O
of O
tacrine O
only O
in O
60 O
% O
of O
animals O
. O

Aventyl O
( O
nortriptyline O
) O
and O
Elavil O
( O
amitriptyline O
) O
each O
produced O
left B
bundle I
branch I
block I
in O
a O
73 O
year O
old O
woman O
. O

Risk O
of O
renal B
failure I
, O
Injury B
to I
the I
kidney I
, O
Failure B
of I
kidney I
function I
, O
Loss B
of I
kidney I
function I
, O
and O
End O
- O
stage O
renal B
damage I
( O
RIFLE O
criteria O
) O
were O
used O
to O
define O
CIN B
and O
its O
incidence O
in O
the O
study O
population O
. O

Risk O
of O
renal B
failure I
, O
Injury B
to I
the I
kidney I
, O
Failure B
of I
kidney I
function I
, O
Loss B
of I
kidney I
function I
, O
and O
End O
- O
stage O
renal B
damage I
( O
RIFLE O
criteria O
) O
were O
used O
to O
define O
CIN B
and O
its O
incidence O
in O
the O
study O
population O
. O

Risk O
of O
renal B
failure I
, O
Injury B
to I
the I
kidney I
, O
Failure B
of I
kidney I
function I
, O
Loss B
of I
kidney I
function I
, O
and O
End O
- O
stage O
renal B
damage I
( O
RIFLE O
criteria O
) O
were O
used O
to O
define O
CIN B
and O
its O
incidence O
in O
the O
study O
population O
. O

Effects O
of O
active O
constituents O
of O
Crocus O
sativus O
L O
. O
, O
crocin O
on O
streptozocin O
- O
induced O
model O
of O
sporadic O
Alzheimer B
' I
s I
disease I
in O
male O
rats O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
crocins O
on O
sporadic O
Alzheimer B
' I
s I
disease I
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin O
( O
STZ O
) O
in O
male O
rats O
was O
investigated O
. O

In O
Alzheimer B
' I
s I
disease I
groups O
, O
rats O
were O
injected O
with O
STZ O
- O
icv O
bilaterally O
( O
3 O
mg O
/ O
kg O
) O
in O
first O
day O
and O
3 O
days O
later O
, O
a O
similar O
STZ O
- O
icv O
application O
was O
repeated O
. O

In O
addition O
, O
crocin O
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning B
and I
memory I
impairment I
in O
treated O
STZ O
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

CONCLUSION O
: O
Therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin O
( O
30 O
mg O
/ O
kg O
) O
in O
antagonizing O
the O
cognitive B
deficits I
caused O
by O
STZ O
- O
icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative B
diseases I
such O
as O
Alzheimer B
' I
s I
disease I
. O

In O
vivo O
characterization O
of O
a O
dual O
adenosine O
A2A O
/ O
A1 O
receptor O
antagonist O
in O
animal O
models O
of O
Parkinson B
' I
s I
disease I
. O

The O
in O
vivo O
characterization O
of O
a O
dual O
adenosine O
A O
( O
2A O
) O
/ O
A O
( O
1 O
) O
receptor O
antagonist O
in O
several O
animal O
models O
of O
Parkinson B
' I
s I
disease I
is O
described O
. O

Compound O
1 O
is O
a O
potent O
A O
( O
2A O
) O
/ O
A O
( O
1 O
) O
receptor O
antagonist O
in O
vitro O
( O
A O
( O
2A O
) O
K O
( O
i O
) O
= O
4 O
. O
1 O
nM O
; O
A O
( O
1 O
) O
K O
( O
i O
) O
= O
17 O
. O
0 O
nM O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
Parkinson B
' I
s I
disease I
including O
mouse O
and O
rat O
models O
of O
haloperidol O
- O
induced O
catalepsy B
, O
mouse O
model O
of O
reserpine O
- O
induced O
akinesia B
, O
rat O
6 O
- O
hydroxydopamine O
( O
6 O
- O
OHDA O
) O
lesion O
model O
of O
drug O
- O
induced O

Bromocriptine O
given O
in O
high O
doses O
has O
been O
associated O
with O
psychosis B
in O
patients O
receiving O
the O
drug O
for O
Parkinson B
' I
s I
disease I
. O

Hyperglycemic B
acidotic I
coma I
and O
death O
in O
Kearns B
- I
Sayre I
syndrome I
. O

This O
paper O
presents O
the O
clinical O
and O
metabolic O
findings O
in O
two O
young O
boys O
with O
long O
- O
standing O
Kearns B
- I
Sayre I
syndrome I
. O

We O
believe O
these O
two O
cases O
represent O
a O
newly O
described O
and O
catastrophic O
metabolic B
- I
endocrine I
failure I
in O
the O
Kearns B
- I
Sayre I
syndrome I
. O

We O
believe O
these O
two O
cases O
represent O
a O
newly O
described O
and O
catastrophic O
metabolic B
- I
endocrine I
failure I
in O
the O
Kearns B
- I
Sayre I
syndrome I
. O

Transketolase O
abnormality O
in O
tolazamide O
- O
induced O
Wernicke B
' I
s I
encephalopathy I
. O

We O
studied O
a O
thiamine O
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic B
patient O
who O
developed O
Wernicke B
' I
s I
encephalopathy I
when O
treated O
with O
tolazamide O
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
Km O
for O
thiamine O
pyrophosphate O
( O
TPP O
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
Wernicke B
- I
Korsakoff I
syndrome I
. O

We O
studied O
a O
thiamine O
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic B
patient O
who O
developed O
Wernicke B
' I
s I
encephalopathy I
when O
treated O
with O
tolazamide O
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
Km O
for O
thiamine O
pyrophosphate O
( O
TPP O
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
Wernicke B
- I
Korsakoff I
syndrome I
. O

In O
addition O
to O
this O
patient O
, O
we O
also O
studied O
this O
enzyme O
from O
three O
diabetic B
kindreds O
without O
any O
history O
of O
Wernicke B
' I
s I
encephalopathy I
and O
from O
four O
normal O
controls O
. O

We O
found O
that O
the O
above O
- O
mentioned O
patient O
and O
one O
of O
the O
diabetic B
kindreds O
with O
no O
history O
of O
Wernicke B
' I
s I
encephalopathy I
had O
abnormal O
transketolase O
as O
determined O
by O
its O
Km O
for O
TPP O
. O

These O
data O
suggest O
a O
similarity O
between O
postalcoholic O
Wernicke B
- I
Korsakoff I
syndrome I
and O
the O
patient O
with O
tolazamide O
- O
induced O
Wernicke B
' I
s I
encephalopathy I
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

These O
data O
suggest O
a O
similarity O
between O
postalcoholic O
Wernicke B
- I
Korsakoff I
syndrome I
and O
the O
patient O
with O
tolazamide O
- O
induced O
Wernicke B
' I
s I
encephalopathy I
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

Clinical O
electrocardiographic O
evolution O
was O
similar O
to O
that O
observed O
in O
Prinzmetal B
' I
s I
angina I
, O
and O
chest B
pain I
promptly O
resolved O
with O
nifedipine O
. O

It O
is O
concluded O
that O
solid O
evidence O
exists O
of O
hepatic B
injury I
due O
to O
amiodarone O
treatment O
, O
including O
steatosis B
, O
alterations O
resembling O
alcoholic B
hepatitis I
, O
cholestatic B
hepatitis I
and O
micronodular O
cirrhosis B
of I
the I
liver I
. O

Induction O
by O
paracetamol O
of O
bladder B
and I
liver I
tumours I
in O
the O
rat O
. O

The O
clinically O
apparent O
occlusion O
may O
be O
preceded O
by O
gastrointestinal B
and I
musculoskeletal I
symptoms I
that O
appear O
to O
be O
ischemic B
in O
origin O
, O
and O
might O
serve O
to O
warn O
the O
clinician O
of O
these O
complications O
. O

Other O
adverse O
reactions O
significantly O
linked O
with O
active O
drugs O
include O
impaired B
glucose I
tolerance I
in O
men O
and O
women O
and O
gout B
in O
men O
, O
associated O
with O
bendrofluazide O
treatment O
, O
and O
Raynaud B
' I
s I
phenomenon I
and O
dyspnoea B
in O
men O
and O
women O
taking O
propranolol O
. O

Nineteen O
patients O
had O
Zollinger B
- I
Ellison I
syndrome I
, O
one O
patient O
had O
systemic B
mastocytosis I
, O
and O
two O
patients O
had O
idiopathic O
hypersecretion O
. O

Treatment O
with O
high O
doses O
of O
cimetidine O
( O
one O
to O
60 O
months O
; O
median O
, O
11 O
months O
) O
or O
ranitidine O
( O
two O
to O
31 O
months O
; O
median O
, O
14 O
months O
) O
was O
not O
associated O
with O
hepatic B
or I
hematologic I
toxicity I
or O
alterations O
of O
serum O
gastrin O
concentrations O
, O
but O
ranitidine O
therapy O
was O
associated O
with O
a O
significantly O
lower O
serum O
creatinine O
level O
than O
seen O
with O
cimetidine O
therapy O
. O

The O
skin B
lesion I
resembled O
elastosis B
perforans I
serpiginosa I
, O
which O
has O
been O
reported O
as O
a O
rare O
side O
effect O
in O
patients O
with O
Wilson B
' I
s I
disease I
but O
not O
in O
patients O
with O
rheumatoid B
arthritis I
treated O
with O
penicillamine O
. O

Laboratory O
testing O
has O
revealed O
a B
falling I
platelet I
count I
, O
increased O
resistance O
to O
heparin O
, O
and O
aggregation O
of O
platelets O
by O
the O
patient O
' O
s O
plasma O
when O
heparin O
is O
added O
. O

The O
20 O
deaths O
, O
52 O
hemorrhagic B
and I
thromboembolic I
complications I
, O
and O
21 O
surgical O
procedures O
to O
manage O
the O
complications O
confirm O
the O
seriousness O
of O
the O
disorder O
. O

The O
most O
common O
symptomatic O
adverse O
reactions O
were O
tremor B
or O
ataxia B
( O
35 O
% O
) O
, O
nausea B
and O
anorexia B
( O
8 O
% O
) O
, O
visual B
halos I
or I
blurring I
( O
6 O
% O
) O
, O
thyroid B
function I
abnormalities I
( O
6 O
% O
) O
and O
pulmonary B
interstitial I
infiltrates I
( O
5 O
% O
) O
. O

Subarachnoid B
and I
cerebral I
hemorrhage I
was O
noted O
in O
18 O
% O
of O
the O
hypertensive B
rats O
. O

Thus O
, O
aminoglycosides O
may O
act O
as O
nephrotoxicants O
at O
glomerular O
and O
/ O
or O
tubular O
level O
inducing O
impairment B
of I
renal I
reabsorption I
and O
accumulation O
of O
proteins O
. O

Induction O
of O
the O
obstructive B
sleep I
apnea I
syndrome I
in O
a O
woman O
by O
exogenous O
androgen O
administration O
. O

Development O
of O
the O
obstructive B
sleep I
apnea I
syndrome I
must O
be O
considered O
a O
possible O
side O
effect O
of O
androgen O
therapy O
. O

Effects O
of O
the O
novel O
compound O
aniracetam O
( O
Ro O
13 O
- O
5057 O
) O
upon O
impaired B
learning I
and I
memory I
in O
rodents O
. O

The O
effect O
of O
calcium O
chloride O
injected O
into O
the O
cerebral O
ventricles O
of O
group O
- O
housed O
unanaesthetized O
cats O
upon O
vocalization O
( O
rage O
, O
hissing O
and O
snarling O
) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting O
) O
, O
mydriasis B
, O
tremor B
and O
clonic B
- I
tonic I
convulsions I
produced O
by O
carbachol O
and O
eserine O
injected O
similarly O
was O
investigated O
. O

On O
the O
other O
hand O
, O
mydriasis B
, O
tremor B
and O
clonic B
- I
tonic I
convulsions I
evoked O
by O
carbachol O
and O
eserine O
were O
not O
significantly O
changed O
by O
calcium O
chloride O
. O

It O
is O
apparent O
that O
calcium O
chloride O
can O
" O
dissociate O
" O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis B
, O
tremor B
and O
clonic B
- I
tonic I
convulsions I
caused O
by O
carbachol O
and O
eserine O
. O

A O
65 O
- O
year O
- O
old O
woman O
with O
adult B
- I
onset I
diabetes I
treated O
with O
chlorpropamide O
( O
Diabenese O
) O
had O
a O
toxic B
optic I
neuropathy I
that O
resolved O
with O
discontinuation O
of O
chlorpropamide O
therapy O
. O

Tests O
used O
to O
evaluate O
the O
changes O
in O
sexual O
behavior O
showed O
a O
significant O
decrease B
in I
sexual I
desire I
, O
sexual O
excitement O
phase O
( O
erection O
) O
, O
and O
frequency O
of O
sexual O
relations O
in O
the O
study O
group O
. O

We O
report O
the O
occurrence O
of O
a O
generalized O
tonic B
- I
clonic I
seizure I
in O
a O
pediatric O
patient O
following O
the O
administration O
of O
flumazenil O
. O

This O
system O
may O
provide O
an O
acute O
model O
in O
which O
to O
study O
the O
pathogenic O
mechanisms O
involved O
in O
steroid B
glaucoma I
and O
primary B
open I
angle I
glaucoma I
. O

The O
safety O
and O
efficacy O
of O
combination O
N O
- O
butyl O
- O
deoxynojirimycin O
( O
SC O
- O
48334 O
) O
and O
zidovudine O
in O
patients O
with O
HIV B
- I
1 I
infection I
and O
200 O
- O
500 O
CD4 O
cells O
/ O
mm3 O
. O

Liposomal O
daunorubicin O
in O
advanced O
Kaposi B
' I
s I
sarcoma I
: O
a O
phase O
II O
study O
. O

We O
report O
a O
non O
- O
randomized O
Phase O
II O
clinical O
trial O
to O
assess O
the O
efficacy O
and O
safety O
of O
liposomal O
daunorubicin O
( O
DaunoXome O
) O
in O
the O
treatment O
of O
AIDS B
related O
Kaposi B
' I
s I
sarcoma I
. O

Eleven O
homosexual O
men O
with O
advanced O
Kaposi B
' I
s I
sarcoma I
were O
entered O
in O
the O
trial O
. O

Stabilization O
of O
Kaposi B
' I
s I
sarcoma I
occurred O
in O
the O
remaining O
six O
, O
maintained O
until O
the O
end O
of O
the O
trial O
period O
in O
four O
. O

In O
this O
small O
patient O
sample O
, O
liposomal O
daunorubicin O
was O
an O
effective O
and O
well O
tolerated O
agent O
in O
the O
treatment O
of O
Kaposi B
' I
s I
sarcoma I
. O

Angioedema B
, O
also O
known O
as O
angioneurotic B
edema I
or O
Quincke B
' I
s I
disease I
, O
is O
a O
well O
- O
demarcated O
, O
localized O
edema B
involving O
the O
subcutaneous O
tissues O
that O
may O
cause O
upper B
- I
airway I
obstruction I
. O

Angioedema B
, O
also O
known O
as O
angioneurotic B
edema I
or O
Quincke B
' I
s I
disease I
, O
is O
a O
well O
- O
demarcated O
, O
localized O
edema B
involving O
the O
subcutaneous O
tissues O
that O
may O
cause O
upper B
- I
airway I
obstruction I
. O

RESULTS O
: O
Impairment B
of I
cognitive I
function I
was O
observed O
6 O
to O
8 O
hours O
after O
administration O
of O
haloperidol O
on O
Day O
2 O
but O
was O
not O
evident O
23 O
hours O
after O
dosing O
. O

Paclitaxel O
( O
Taxol O
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
has O
demonstrated O
significant O
antineoplastic O
activity O
against O
different O
tumor B
types O
, O
notably O
ovarian B
and I
breast I
carcinoma I
. O

Nutritional O
intake O
, O
measured O
daily O
in O
15 O
animals O
, O
showed O
a O
significant O
reduction B
of I
food I
intake I
in O
the O
steroid O
- O
treated O
groups O
( O
- O
50 O
and O
- O
79 O
% O
in O
M O
and O
T O
, O
respectively O
) O
. O

This O
was O
associated O
with O
a O
similar O
loss B
in I
body I
weight I
. O

Leg B
and I
back I
pain I
after O
spinal O
anaesthesia O
involving O
hyperbaric O
5 O
% O
lignocaine O
. O

The O
findings O
suggest O
that O
NIK O
- O
247 O
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
Alzheimer B
' I
s I
disease I
. O

The O
clinical O
utility O
of O
dopamine O
( O
DA O
) O
D1 O
receptor O
agonists O
in O
the O
treatment O
of O
Parkinson B
' I
s I
disease I
( O
PD B
) O
is O
still O
unclear O
. O

Posteroventral O
medial O
pallidotomy O
in O
advanced O
Parkinson B
' I
s I
disease I
. O

BACKGROUND O
: O
Posteroventral O
medial O
pallidotomy O
sometimes O
produces O
striking O
improvement O
in O
patients O
with O
advanced O
Parkinson B
' I
s I
disease I
, O
but O
the O
studies O
to O
date O
have O
involved O
small O
numbers O
of O
patients O
and O
short O
- O
term O
follow O
- O
up O
. O

METHODS O
: O
Forty O
patients O
with O
Parkinson B
' I
s I
disease I
underwent O
serial O
, O
detailed O
assessments O
both O
after O
drug O
withdrawal O
( O
" O
off O
" O
period O
) O
and O
while O
taking O
their O
optimal O
medical O
regimens O
( O
" O
on O
" O
period O
) O
. O

CONCLUSIONS O
: O
In O
late O
- O
stage O
Parkinson B
' I
s I
disease I
, O
pallidotomy O
significantly O
reduces O
levodopa O
- O
induced O
dyskinesias B
and O
off O
- O
period O
disability O
. O

Effect O
of O
glyceryl O
trinitrate O
on O
the O
sphincter B
of I
Oddi I
spasm I
evoked O
by O
prostigmine O
- O
morphine O
administration O
. O

OBJECTIVE O
: O
In O
this O
study O
the O
effect O
of O
glyceryl O
trinitrate O
on O
the O
prostigmine O
- O
morphine O
- O
induced O
sphincter B
of I
Oddi I
spasm I
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter B
of I
Oddi I
dyskinesia I
. O

OBJECTIVE O
: O
In O
this O
study O
the O
effect O
of O
glyceryl O
trinitrate O
on O
the O
prostigmine O
- O
morphine O
- O
induced O
sphincter B
of I
Oddi I
spasm I
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter B
of I
Oddi I
dyskinesia I
. O

METHOD O
: O
Sphincter B
of I
Oddi I
spasm I
was O
induced O
by O
prostigmine O
- O
morphine O
administration O
( O
0 O
. O
5 O
mg O
prostigmine O
intramuscularly O
and O
10 O
mg O
morphine O
subcutaneously O
) O
and O
visualized O
by O
quantitative O
hepatobiliary O
scintigraphy O
. O

CONCLUSION O
: O
These O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl O
trinitrate O
on O
the O
morphine O
- O
induced O
sphincter B
of I
Oddi I
spasm I
in O
humans O
. O

Since O
glyceryl O
trinitrate O
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine O
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter B
of I
Oddi I
dyskinesia I
. O

Prolongation B
of I
QT I
interval I
, O
torsades B
de I
pointes I
, O
and O
sudden B
cardiac I
death I
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin O
or O
azole O
antifungal O
agents O
, O
but O
not O
with O
other O
CYP3A4 O
inhibitors O
. O

The O
patient O
was O
in O
near O
syncope B
and O
had O
QT B
- I
interval I
prolongation I
. O

However O
, O
the O
use O
of O
CBDCA O
higher O
- O
intensity O
schedules O
and O
the O
association O
with O
other O
neurotoxic B
drugs O
in O
polychemotherapy O
may O
cause O
some O
concern O
about O
its O
safety O
with O
respect O
to O
peripheral B
nervous I
system I
damage I
. O

One O
epileptic B
woman O
delivered O
a O
newborn O
with O
cleft B
lip I
and I
palate I
. O

The O
primary O
outcome O
was O
new O
or O
worsening O
valvulopathy B
, O
defined O
as O
progression O
of O
either O
aortic B
or I
mitral I
regurgitation I
by O
at O
least O
one O
degree O
of O
severity O
and O
disease O
that O
met O
U O
. O
S O
. O

